Brief: Nektar Therapeutics Q2 EPS USD -1.23
13/08/2026 21:16
BRIEF-Nektar Therapeutics Q2 EPS USD -1.23 Aug 13 (Reuters) - Nektar Therapeutics Q2 net income USD -40.622 million.
- Q2 product sales USD 10.131 million
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says